BLCO logo

Bausch + Lomb Corporation Stock Price

NYSE:BLCO Community·US$5.5b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

BLCO Share Price Performance

US$15.18
3.20 (26.71%)
US$17.25
Fair Value
US$15.18
3.20 (26.71%)
12.0% undervalued intrinsic discount
US$17.25
Fair Value
Price US$15.18
AnalystConsensusTarget US$17.25
CG86 US$39.23
AnalystLowTarget US$13.00

BLCO Community Narratives

·
Fair Value US$17.25 12.0% undervalued intrinsic discount

Dry Eye Treatments And Aging Demographics Will Drive Long Term Eye Care Demand

1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Fair Value
·
Fair Value US$39.23 61.3% undervalued intrinsic discount

$BLCO & $COO The Silence BEFORE the AGM: A Retail Investor’s Timeline, Findings, and Opinion on SUSPICIOUS SILENCE!

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
·
Fair Value US$13 16.8% overvalued intrinsic discount

Dry Eye Dependence And Execution Risks Will Undermine Long Term Earnings Quality

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$39.23
61.3% undervalued intrinsic discount
Fair Value
Profit Margin
13.36%
Future PE
24.95x
Price in 2031
US$61.27
US$13
16.8% overvalued intrinsic discount
Profit Margin
4.28%
Future PE
24.41x
Price in 2029
US$16.77
US$17.25
12.0% undervalued intrinsic discount
Profit Margin
4.3%
Future PE
31.72x
Price in 2028
US$22.26
US$21
27.7% undervalued intrinsic discount
Profit Margin
0.04%
Future PE
40.17x
Price in 2028
US$0.27

Trending Discussion

Updated Narratives

BLCO logo

$BLCO & $COO The Silence BEFORE the AGM: A Retail Investor’s Timeline, Findings, and Opinion on SUSPICIOUS SILENCE!

Fair Value: US$39.23 61.3% undervalued intrinsic discount
5 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BLCO logo

Dry Eye Dependence And Execution Risks Will Undermine Long Term Earnings Quality

Fair Value: US$13 16.8% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
BLCO logo

Dry Eye Treatments And Aging Demographics Will Drive Long Term Eye Care Demand

Fair Value: US$17.25 12.0% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with moderate growth potential.

0 Risks
3 Rewards

Bausch + Lomb Corporation Key Details

US$5.2b

Revenue

US$2.1b

Cost of Revenue

US$3.2b

Gross Profit

US$3.4b

Other Expenses

-US$219.0m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.61
60.62%
-4.21%
78.6%
View Full Analysis

About BLCO

Founded
1853
Employees
13000
CEO
Brenton Saunders
WebsiteView website
www.bausch.com

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Recent BLCO News & Updates

Seeking Alpha May 26

Bausch + Lomb: Even Though Growth Continues, I Don't See A Way Higher

Summary Bausch + Lomb delivers strong revenue growth and improving profitability, but the share price remains in fair value territory, warranting a 'Hold' rating. BLCO's Vision Care segment, driven by Lumify and SiHy Daily lenses, is a key growth engine with new product launches planned through 2029. Pharmaceuticals and Surgical segments show robust sales and profit gains, supported by innovative products like MIEBO, XIIDRA, and enVista Envy. Management raised 2026 revenue guidance to $5.42–$5.52 billion and EBITDA to $1.01–$1.06 billion, but valuation is not compelling versus peers. Read the full article on Seeking Alpha

Recent updates

No updates